- With respect to the primary and secondary endpoints, Athersys's (NASDAQ:ATHX) Multistem ischemic stroke therapy did not show a difference at 90 days compared to placebo.
- But the treatment was associated with lower rates of mortality and life threatening adverse events, infections and pulmonary events.
- Management: "While the trial did not achieve the primary or component secondary endpoints, we believe the evidence indicating that patients who received MultiStem treatment early appeared to exhibit meaningfully better recovery is very important and promising."
- ATHX is down 28.5% since Tuesday.
- Source: Press Release
- Related: Athersys: Where Is The Run Up Before The Binary Event? (Apr. 13)
- Related: Athersys: An Ischemic Stroke Holy Grail? Find Out In Less Than A Month (Mar. 24)
- Related: Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2014 Results - Earnings Call Transcript (Mar. 12)
Athersys's MultiStem therapy fails to meet primary endpoint
Recommended For You
About ATHXQ Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ATHXQ | - | - |
| Athersys, Inc. | ||